A Phase 1 Study of LY4050784 in People With Advanced Solid Tumors

Full Title

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

Purpose

Researchers want to find the best dose of LY4050784 to treat advanced solid tumors. The people in this study have cancer that cannot be cured with standard therapies. Their tumors also have a mutation (change) in the SMARCA4 and/or BRG1 genes, which play a role in cancer growth.

LY4050784 targets cancer cells that make a gene called SMARCA2/BRM. The molecules of these drugs are small enough to enter cells easily. Once inside the cells, they can affect other molecules, such as proteins, and cause cancer cells to die. LY4050784 is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call 646-888-4226.